Interactions between Ethosuximide and Lumryz

The sodium oxybate in Lumryz has a major potential interaction with Alcoholism.

Sodium oxybate should not be used with alcohol. This drug should be used with caution in patients with history of drug or alcohol abuse. The inappropriate use of this drug alone or in combination with other CNS depressants is associated with CNS adverse reaction including seizures, respiratory depression, decreases in the levels of consciousness, coma and death. Because illicit use and abuse has been reported, physicians should evaluate carefully their patients for history of drug or alcohol abuse and should follow such patients closely, observing them for signs of misuse.

Ethosuximide has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants. Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported. Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression. Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy. Marked depression of blood counts may be indication for withdrawal of succinimide therapy.

The sodium oxybate in Lumryz has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Ethosuximide has a moderate potential interaction with Depression.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

The sodium oxybate in Lumryz has a major potential interaction with Drug Dependence.

Sodium oxybate should not be used with alcohol. This drug should be used with caution in patients with history of drug or alcohol abuse. The inappropriate use of this drug alone or in combination with other CNS depressants is associated with CNS adverse reaction including seizures, respiratory depression, decreases in the levels of consciousness, coma and death. Because illicit use and abuse has been reported, physicians should evaluate carefully their patients for history of drug or alcohol abuse and should follow such patients closely, observing them for signs of misuse.

The sodium oxybate in Lumryz has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The sodium oxybate in Lumryz has a moderate potential interaction with Heart Disease.

Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.

Ethosuximide has a moderate potential interaction with Hemodialysis.

Ethosuximide has been shown to be removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.

The sodium oxybate in Lumryz has a moderate potential interaction with High Blood Pressure.

Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.

The sodium oxybate in Lumryz has a moderate potential interaction with Hypertensive Heart with CHF and Renal Disease.

Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.

Ethosuximide has a major potential interaction with Liver Disease.

Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals. In humans, abnormalities in liver and renal function studies have been reported. Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases. Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.

The sodium oxybate in Lumryz has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Ethosuximide has a major potential interaction with Lupus Erythematosus.

Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide. Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after. Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.

The sodium oxybate in Lumryz has a moderate potential interaction with Narcolepsy.

The use of sodium oxybate may impair the respiratory drive especially in patients with compromised respiratory function. Sodium oxybate should be used cautiously in patients with sleep apnea and sleep-related breathing disorders as there have been reports of increased central apneas and clinically relevant desaturation. Prescribers should be aware that sleep-related disorders tend to be more prevalent in obese patients, postmenopausal women not receiving hormone replacement therapy and also among patients with narcolepsy.

Ethosuximide has a moderate potential interaction with Psychosis.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

Ethosuximide has a major potential interaction with Renal Dysfunction.

Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals. In humans, abnormalities in liver and renal function studies have been reported. Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases. Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.

The sodium oxybate in Lumryz has a moderate potential interaction with Renal Dysfunction.

Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.

The sodium oxybate in Lumryz has a moderate potential interaction with Sleep Apnea.

The use of sodium oxybate may impair the respiratory drive especially in patients with compromised respiratory function. Sodium oxybate should be used cautiously in patients with sleep apnea and sleep-related breathing disorders as there have been reports of increased central apneas and clinically relevant desaturation. Prescribers should be aware that sleep-related disorders tend to be more prevalent in obese patients, postmenopausal women not receiving hormone replacement therapy and also among patients with narcolepsy.

The sodium oxybate in Lumryz has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The sodium oxybate in Lumryz has a moderate potential interaction with Weight Loss.

The use of sodium oxybate may impair the respiratory drive especially in patients with compromised respiratory function. Sodium oxybate should be used cautiously in patients with sleep apnea and sleep-related breathing disorders as there have been reports of increased central apneas and clinically relevant desaturation. Prescribers should be aware that sleep-related disorders tend to be more prevalent in obese patients, postmenopausal women not receiving hormone replacement therapy and also among patients with narcolepsy.